Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Harvard Business School
Express Scripts
McKinsey
Johnson and Johnson

Last Updated: November 26, 2022

Details for Patent: 8,071,644


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,071,644 protect, and when does it expire?

Patent 8,071,644 protects EPIDUO and is included in one NDA.

This patent has thirty-five patent family members in twenty-two countries.

Summary for Patent: 8,071,644
Title:Combinations of adapalene and benzoyl peroxide for treating acne lesions
Abstract: Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO.
Inventor(s): Abou-Chacra Vernet; Marie-line (Nice, FR), Gross; Denis (Callian, FR), Loesche; Christian (Valbonne, FR), Poncet; Michel (Mougins, FR)
Assignee: Galderma Research & Development (Biot, FR)
Application Number:12/318,937
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,071,644
Patent Claim Types:
see list of patent claims
Use; Compound;

Drugs Protected by US Patent 8,071,644

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galderma Labs Lp EPIDUO adapalene; benzoyl peroxide GEL;TOPICAL 022320-001 Dec 8, 2008 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y TREATMENT OF ACNE See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,071,644

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France06 52968Jul 13, 2006

International Family Members for US Patent 8,071,644

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 061989 See Plans and Pricing
Australia 2007274288 See Plans and Pricing
Brazil PI0713182 See Plans and Pricing
Canada 2656456 See Plans and Pricing
China 101541320 See Plans and Pricing
Colombia 6150136 See Plans and Pricing
Cyprus 1114473 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Baxter
Moodys
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.